伐尼克兰在慢性阻塞性肺疾病患者戒烟治疗中的作用

摘要

目的 评估伐尼克兰戒除轻中度慢性阻塞性肺疾病(COPD)吸烟患者尼古丁依赖(烟瘾)的有效性和安全性.方法 COPD尼古丁依赖患者50例,分为治疗组和对照组各25例,采用随机、双盲、安慰药对照,治疗组给予伐尼克兰0.5～2.0 mg·d-1;对照组给予等剂量的安慰药.治疗期和治疗后的随访期均为12周.结果 治疗组和对照组在治疗期最后4周的持续戒断患者分别为13和8例;第9～24周的持续戒断患者分别为8和5例;第12周的7 d时点戒烟患者分别为14和8例;第24周7 d时点戒烟患者分别为9和6例;发生不良反应均为2例.结论 伐尼克兰用于戒除轻中度COPD患者尼古丁依赖安全,有效.%Objective To evaluate the effecacy and safety of varenicline on smoking cessation intervention for patients with chronic obstructive pulmonary disease (COPD). Methods 50 nicotine-dependent patients with COPD were divided into therapeutic and control groups. In a randomized, double-blind, placebo-controlled study, patients in the therapeutic group received varenicline 0. 5 ～ 2.0 mg· d -1. Patients were followed up for 12 weeks after treatment. Results Week 9-12 CAR was significantly higher for varenicline ( 13 ) versus placebo (8); CARs through 12 weeks post-treatment ( weeks 9-24) were 8 with varenicline and 5 with placebo. The 7-day PP was 14 with varenicline versus 8 with placebo at week 12, and 9 versus 6 with placebo at week 24. Reports of depression, depressed mood, and depressive symptoms were similar for both treatment groups .Conclusion Varenicline is an efficacious and well tolerated pharmacologic treatment for smoking cessation among patients with mild moderate COPD.